{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,12,5]],"date-time":"2025-12-05T12:28:45Z","timestamp":1764937725053},"reference-count":56,"publisher":"Tohoku University Medical Press","issue":"3","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Tohoku J. Exp. Med."],"published-print":{"date-parts":[[2024]]},"DOI":"10.1620\/tjem.2024.j026","type":"journal-article","created":{"date-parts":[[2024,4,24]],"date-time":"2024-04-24T22:14:59Z","timestamp":1713996899000},"page":"175-184","source":"Crossref","is-referenced-by-count":1,"title":["Efficacy and Safety of Neoadjuvant Pyrotinib for Human Epidermal Receptor 2-Positive Breast Cancer: A Meta-Analysis"],"prefix":"10.1620","volume":"263","author":[{"given":"Xiaona","family":"Lin","sequence":"first","affiliation":[{"name":"Department of Breast and Thyroid Surgery, Zibo Central Hospital"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Xiao","family":"Liu","sequence":"additional","affiliation":[{"name":"Department of Ultrasound, Zibo Central Hospital"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Xiaohui","family":"Yang","sequence":"additional","affiliation":[{"name":"Department of Anesthesia Surgery, Zibo Central Hospital"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Feng","family":"Sun","sequence":"additional","affiliation":[{"name":"Department of Breast and Thyroid Surgery, Zibo Central Hospital"}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"622","reference":[{"key":"1","doi-asserted-by":"crossref","unstructured":"Aapro, M., Cardoso, F., Curigliano, G., Eniu, A., Gligorov, J., Harbeck, N., Mueller, A., Pagani, O., Paluch-Shimon, S., Senkus, E., Thurlimann, B. &amp; Zaman, K. (2022)  Current challenges and unmet needs in treating patients with human epidermal growth factor receptor 2-positive advanced breast cancer.  <i>Breast<\/i>, 66, 145-156.","DOI":"10.1016\/j.breast.2022.07.011"},{"key":"2","doi-asserted-by":"crossref","unstructured":"Broglio, K.R., Quintana, M., Foster, M., Olinger, M., McGlothlin, A., Berry, S.M., Boileau, J.F., Brezden-Masley, C., Chia, S., Dent, S., Gelmon, K., Paterson, A., Rayson, D. &amp; Berry, D.A. (2016)  Association of Pathologic Complete Response to Neoadjuvant Therapy in HER2-Positive Breast Cancer With Long-Term Outcomes: A Meta-Analysis.  <i>JAMA Oncol.<\/i>, 2, 751-760.","DOI":"10.1001\/jamaoncol.2015.6113"},{"key":"3","doi-asserted-by":"crossref","unstructured":"Davey, M.G., Browne, F., Miller, N., Lowery, A.J. &amp; Kerin, M.J. (2022)  Pathological complete response as a surrogate to improved survival in human epidermal growth factor receptor-2-positive breast cancer: systematic review and meta-analysis.  <i>BJS Open<\/i>, 6, zrac028.","DOI":"10.1093\/bjsopen\/zrac028"},{"key":"4","doi-asserted-by":"crossref","unstructured":"Denkert, C., von Minckwitz, G., Darb-Esfahani, S., Lederer, B., Heppner, B.I., Weber, K.E., Budczies, J., Huober, J., Klauschen, F., Furlanetto, J., Schmitt, W.D., Blohmer, J.U., Karn, T., Pfitzner, B.M., Kummel, S., et al.  (2018)  Tumour-infiltrating lymphocytes and prognosis in different subtypes of breast cancer: a pooled analysis of 3771 patients treated with neoadjuvant therapy.  <i>Lancet Oncol.<\/i>, 19, 40-50.","DOI":"10.1016\/S1470-2045(17)30904-X"},{"key":"5","doi-asserted-by":"crossref","unstructured":"Derakhshani, A., Rezaei, Z., Safarpour, H., Sabri, M., Mir, A., Sanati, M.A., Vahidian, F., Gholamiyan Moghadam, A., Aghadoukht, A., Hajiasgharzadeh, K. &amp; Baradaran, B. (2020)  Overcoming trastuzumab resistance in HER2-positive breast cancer using combination therapy.  <i>J. Cell. Physiol.<\/i>, 235, 3142-3156.","DOI":"10.1002\/jcp.29216"},{"key":"6","doi-asserted-by":"crossref","unstructured":"Ding, X., Mo, W., Xie, X., Wang, O., Ding, Y., Zhao, S., He, X., Feng, W., Zou, D. &amp; Yang, H. (2021)  Pyrotinib as neoadjuvant therapy for HER2+ breast cancer: A multicenter, randomized, controlled, phase II trial, <i>J. Clin. Oncol.<\/i>, 39, 574-574.","DOI":"10.1200\/JCO.2021.39.15_suppl.574"},{"key":"7","doi-asserted-by":"crossref","unstructured":"Ding, Y., Mo, W., Xie, X., Wang, O., He, X., Zhao, S., Gu, X., Liang, C., Qin, C., Ding, K., Yang, H. &amp; Ding, X. (2023)  Neoadjuvant Pyrotinib plus Trastuzumab, Docetaxel, and Carboplatin in Early or Locally Advanced Human Epidermal Receptor 2-Positive Breast Cancer in China: A Multicenter, Randomized, Double-Blind, Placebo-Controlled Phase 2 Trial.  <i>Oncol. Res. Treat.<\/i>, 46, 303-311.","DOI":"10.1159\/000531492"},{"key":"8","doi-asserted-by":"crossref","unstructured":"Duan, T., Cil, O., Thiagarajah, J.R. &amp; Verkman, A.S. (2019)  Intestinal epithelial potassium channels and CFTR chloride channels activated in ErbB tyrosine kinase inhibitor diarrhea.  <i>JCI Insight<\/i>, 4, e126444.","DOI":"10.1172\/jci.insight.126444"},{"key":"9","doi-asserted-by":"crossref","unstructured":"Fang, C., Wen, J., Kang, M., Zhang, Y., Chen, Q. &amp; Ren, L. (2022)  Incidence and management of pyrotinib-associated diarrhea in HER2-positive advanced breast cancer patients.  <i>Ann. Palliat. Med.<\/i>, 11, 210-216.","DOI":"10.21037\/apm-21-3978"},{"key":"10","doi-asserted-by":"crossref","unstructured":"Fazal, F., Bashir, M.N., Adil, M.L., Tanveer, U., Ahmed, M., Chaudhry, T.Z., Ijaz, A.A. &amp; Haider, M. (2023)  Pathologic Complete Response Achieved in Early-Stage HER2-Positive Breast Cancer After Neoadjuvant Therapy With Trastuzumab and Chemotherapy vs. Trastuzumab, Chemotherapy, and Pertuzumab: A Systematic Review and Meta-Analysis of Clinical Trials.  <i>Cureus<\/i>, 15, e39780.","DOI":"10.7759\/cureus.39780"},{"key":"11","unstructured":"Fu, C.B., Han, H., Lin, S.G. &amp; Xu, C.S. (2023)  A retrospective clinicaI study of pyrotinib in combination with trastuzumab and pertuzumab in neoadjuvant therapy for HER-2 positive breast cancer.  <i>Chin. J. Clin. Oncol.<\/i>, 50, 882-887."},{"key":"12","doi-asserted-by":"crossref","unstructured":"Gianni, L., Pienkowski, T., Im, Y.H., Tseng, L.M., Liu, M.C., Lluch, A., Staroslawska, E., de la Haba-Rodriguez, J., Im, S.A., Pedrini, J.L., Poirier, B., Morandi, P., Semiglazov, V., Srimuninnimit, V., Bianchi, G.V., et al.  (2016)  5-year analysis of neoadjuvant pertuzumab and trastuzumab in patients with locally advanced, inflammatory, or early-stage HER2-positive breast cancer (NeoSphere): a multicentre, open-label, phase 2 randomised trial.  <i>Lancet Oncol.<\/i>, 17, 791-800.","DOI":"10.1016\/S1470-2045(16)00163-7"},{"key":"13","doi-asserted-by":"crossref","unstructured":"Gunasekara, A.D.M., Anothaisintawee, T., Youngkong, S., Ha, N.T., McKay, G.J., Attia, J. &amp; Thakkinstian, A. (2022)  Neoadjuvant Treatment with HER2-Targeted Therapies in HER2-Positive Breast Cancer: A Systematic Review and Network Meta-Analysis.  <i>Cancers <\/i>(<i>Basel<\/i>), 14, 523.","DOI":"10.3390\/cancers14030523"},{"key":"14","doi-asserted-by":"crossref","unstructured":"Higgins, J.P., Thompson, S.G., Deeks, J.J. &amp; Altman, D.G. (2003)  Measuring inconsistency in meta-analyses.  <i>BMJ<\/i>, 327, 557-560.","DOI":"10.1136\/bmj.327.7414.557"},{"key":"15","doi-asserted-by":"crossref","unstructured":"Hu, W., Yang, J., Zhang, Z., Xu, D. &amp; Li, N. (2023)  Pyrotinib for HER2-positive metastatic breast cancer: a systematic review and meta-analysis.  <i>Transl. Cancer Res.<\/i>, 12, 247-256.","DOI":"10.21037\/tcr-22-1746"},{"key":"16","doi-asserted-by":"crossref","unstructured":"Hutton, B., Salanti, G., Caldwell, D.M., Chaimani, A., Schmid, C.H., Cameron, C., Ioannidis, J.P., Straus, S., Thorlund, K., Jansen, J.P., Mulrow, C., Catala-Lopez, F., Gotzsche, P.C., Dickersin, K., Boutron, I., et al.  (2015)  The PRISMA extension statement for reporting of systematic reviews incorporating network meta-analyses of health care interventions: checklist and explanations.  <i>Ann. Intern. Med.<\/i>, 162, 777-784.","DOI":"10.7326\/M14-2385"},{"key":"17","doi-asserted-by":"crossref","unstructured":"Jackisch, C., Lammers, P. &amp; Jacobs, I. (2017)  Evolving landscape of human epidermal growth factor receptor 2-positive breast cancer treatment and the future of biosimilars.  <i>Breast<\/i>, 32, 199-216.","DOI":"10.1016\/j.breast.2017.01.010"},{"key":"18","doi-asserted-by":"crossref","unstructured":"Jagosky, M. &amp; Tan, A.R. (2021)  Combination of Pertuzumab and Trastuzumab in the Treatment of HER2-Positive Early Breast Cancer: A Review of the Emerging Clinical Data.  <i>Breast Cancer <\/i>(<i>Dove Med Press<\/i>), 13, 393-407.","DOI":"10.2147\/BCTT.S176514"},{"key":"19","doi-asserted-by":"crossref","unstructured":"Korde, L.A., Somerfield, M.R., Carey, L.A., Crews, J.R., Denduluri, N., Hwang, E.S., Khan, S.A., Loibl, S., Morris, E.A., Perez, A., Regan, M.M., Spears, P.A., Sudheendra, P.K., Symmans, W.F., Yung, R.L., et al.  (2021)  Neoadjuvant Chemotherapy, Endocrine Therapy, and Targeted Therapy for Breast Cancer: ASCO Guideline.  <i>J. Clin. Oncol.<\/i>, 39, 1485-1505.","DOI":"10.1200\/JCO.20.03399"},{"key":"20","doi-asserted-by":"crossref","unstructured":"Lai, J., Zhuo, X., Yin, K., Jiang, F., Liu, L., Xu, X., Liu, H., Wang, J., Zhao, J., Xu, W., Yang, S., Guo, H., Yuan, X., Lin, X., Qi, F., et al.  (2023)  Potential mechanism of pyrotinib-induced diarrhea was explored by gut microbiome and ileum metabolomics.  <i>Anticancer Drugs<\/i>, 34, 747-762.","DOI":"10.1097\/CAD.0000000000001440"},{"key":"21","doi-asserted-by":"crossref","unstructured":"Li, C., Bian, X., Liu, Z., Wang, X., Song, X., Zhao, W., Liu, Y. &amp; Yu, Z. (2021a)  Effectiveness and safety of pyrotinib-based therapy in patients with HER2-positive metastatic breast cancer: A real-world retrospective study.  <i>Cancer Med.<\/i>, 10, 8352-8364.","DOI":"10.1002\/cam4.4335"},{"key":"22","doi-asserted-by":"crossref","unstructured":"Li, Q., Wang, Y., Zhu, M., Gu, Y. &amp; Tang, Y. (2021b)  Clinical observation of neoadjuvant chemotherapy with pyrotinib plus trastuzumab in HER2-positive breast cancer: a cohort study.  <i>Gland Surg.<\/i>, 10, 3389-3402.","DOI":"10.21037\/gs-21-794"},{"key":"23","doi-asserted-by":"crossref","unstructured":"Li, X., Yang, C., Wan, H., Zhang, G., Feng, J., Zhang, L., Chen, X., Zhong, D., Lou, L., Tao, W. &amp; Zhang, L. (2017)  Discovery and development of pyrotinib: A novel irreversible EGFR\/HER2 dual tyrosine kinase inhibitor with favorable safety profiles for the treatment of breast cancer.  <i>Eur. J. Pharm. Sci.<\/i>, 110, 51-61.","DOI":"10.1016\/j.ejps.2017.01.021"},{"key":"24","doi-asserted-by":"crossref","unstructured":"Liao, H., Huang, W., Liu, Y., Pei, W. &amp; Li, H. (2021)  Efficacy and Safety of Pyrotinib Versus T-DM1 in HER2+ Metastatic Breast Cancer Patients Pre-Treated With Trastuzumab and a Taxane: A Bayesian Network Meta-Analysis.  <i>Front. Oncol.<\/i>, 11, 608781.","DOI":"10.3389\/fonc.2021.608781"},{"key":"25","doi-asserted-by":"crossref","unstructured":"Liu, L., Zhu, M., Wang, Y., Li, M. &amp; Gu, Y. (2023)  Neoadjuvant pyrotinib plus trastuzumab and chemotherapy for HER2-positive breast cancer: a prospective cohort study.  <i>World J. Surg. Oncol.<\/i>, 21, 389.","DOI":"10.1186\/s12957-023-03266-5"},{"key":"26","doi-asserted-by":"crossref","unstructured":"Loibl, S. &amp; Gianni, L. (2017)  HER2-positive breast cancer.  <i>Lancet<\/i>, 389, 2415-2429.","DOI":"10.1016\/S0140-6736(16)32417-5"},{"key":"27","doi-asserted-by":"crossref","unstructured":"Loibl, S., Poortmans, P., Morrow, M., Denkert, C. &amp; Curigliano, G. (2021)  Breast cancer.  <i>Lancet<\/i>, 397, 1750-1769.","DOI":"10.1016\/S0140-6736(20)32381-3"},{"key":"28","doi-asserted-by":"crossref","unstructured":"Lundh, A. &amp; Gotzsche, P.C. (2008)  Recommendations by Cochrane Review Groups for assessment of the risk of bias in studies.  <i>BMC Med. Res. Methodol.<\/i>, 8, 22.","DOI":"10.1186\/1471-2288-8-22"},{"key":"29","doi-asserted-by":"crossref","unstructured":"Ma, F., Yan, M., Li, W., Ouyang, Q., Tong, Z., Teng, Y., Wang, Y., Wang, S., Geng, C., Luo, T., Zhong, J., Zhang, Q., Liu, Q., Zeng, X., Sun, T., et al.  (2023)  Pyrotinib versus placebo in combination with trastuzumab and docetaxel as first line treatment in patients with HER2 positive metastatic breast cancer (PHILA): randomised, double blind, multicentre, phase 3 trial.  <i>BMJ<\/i>, 383, e076065.","DOI":"10.1136\/bmj-2023-076065"},{"key":"30","doi-asserted-by":"crossref","unstructured":"Ma, X., Li, Y., Li, L., Gao, C., Liu, D., Li, H., Zhao, Z. &amp; Zhao, B. (2022)  Pyrotinib-based treatments in HER2-positive breast cancer patients with brain metastases.  <i>Ann. Med.<\/i>, 54, 3085-3095.","DOI":"10.1080\/07853890.2022.2139411"},{"key":"31","doi-asserted-by":"crossref","unstructured":"Mao, X., Lv, P., Gong, Y., Wu, X., Tang, P., Wang, S., Zhang, D., You, W., Wang, O., Zhou, J., Li, J. &amp; Jin, F. (2022)  Pyrotinib-Containing Neoadjuvant Therapy in Patients With HER2-Positive Breast Cancer: A Multicenter Retrospective Analysis.  <i>Front. Oncol.<\/i>, 12, 855512.","DOI":"10.3389\/fonc.2022.855512"},{"key":"32","doi-asserted-by":"crossref","unstructured":"Martinez-Saez, O. &amp; Prat, A. (2021)  Current and Future Management of HER2-Positive Metastatic Breast Cancer.  <i>JCO Oncol. Pract.<\/i>, 17, 594-604.","DOI":"10.1200\/OP.21.00172"},{"key":"33","doi-asserted-by":"crossref","unstructured":"Nielsen, D.L., Andersson, M. &amp; Kamby, C. (2009)  HER2-targeted therapy in breast cancer.  Monoclonal antibodies and tyrosine kinase inhibitors.  <i>Cancer Treat. Rev.<\/i>, 35, 121-136.","DOI":"10.1016\/j.ctrv.2008.09.003"},{"key":"34","doi-asserted-by":"crossref","unstructured":"Qi, X., Shi, Q., Xuhong, J., Zhang, Y. &amp; Jiang, J. (2023)  Pyrotinib-based therapeutic approaches for HER2-positive breast cancer: the time is now.  <i>Breast Cancer Res.<\/i>, 25, 113.","DOI":"10.1186\/s13058-023-01694-5"},{"key":"35","doi-asserted-by":"crossref","unstructured":"Schlam, I. &amp; Swain, S.M. (2021)  HER2-positive breast cancer and tyrosine kinase inhibitors: the time is now.  <i>NPJ Breast Cancer<\/i>, 7, 56.","DOI":"10.1038\/s41523-021-00265-1"},{"key":"36","doi-asserted-by":"crossref","unstructured":"Shyam Sunder, S., Sharma, U.C. &amp; Pokharel, S. (2023)  Adverse effects of tyrosine kinase inhibitors in cancer therapy: pathophysiology, mechanisms and clinical management.  <i>Signal Transduct. Target. Ther.<\/i>, 8, 262.","DOI":"10.1038\/s41392-023-01469-6"},{"key":"37","doi-asserted-by":"crossref","unstructured":"Singh, D.D., Lee, H.J. &amp; Yadav, D.K. (2022)  Clinical updates on tyrosine kinase inhibitors in HER2-positive breast cancer.  <i>Front. Pharmacol.<\/i>, 13, 1089066.","DOI":"10.3389\/fphar.2022.1089066"},{"key":"38","doi-asserted-by":"crossref","unstructured":"Singla, H. &amp; Munshi, A. (2020)  HER2 Tyrosine Kinase Inhibitors in the Sensitization to Cancers Resistant to HER2 Antibodies.  <i>Crit. Rev. Oncog.<\/i>, 25, 241-250.","DOI":"10.1615\/CritRevOncog.2020037108"},{"key":"39","doi-asserted-by":"crossref","unstructured":"Spring, L.M., Fell, G., Arfe, A., Sharma, C., Greenup, R., Reynolds, K.L., Smith, B.L., Alexander, B., Moy, B., Isakoff, S.J., Parmigiani, G., Trippa, L. &amp; Bardia, A. (2020)  Pathologic Complete Response after Neoadjuvant Chemotherapy and Impact on Breast Cancer Recurrence and Survival: A Comprehensive Meta-analysis.  <i>Clin. Cancer Res.<\/i>, 26, 2838-2848.","DOI":"10.1158\/1078-0432.CCR-19-3492"},{"key":"40","doi-asserted-by":"crossref","unstructured":"Sung, H., Ferlay, J., Siegel, R.L., Laversanne, M., Soerjomataram, I., Jemal, A. &amp; Bray, F. (2021)  Global Cancer Statistics 2020: GLOBOCAN Estimates of Incidence and Mortality Worldwide for 36 Cancers in 185 Countries.  <i>CA Cancer J. Clin.<\/i>, 71, 209-249.","DOI":"10.3322\/caac.21660"},{"key":"41","doi-asserted-by":"crossref","unstructured":"Swain, S.M., Shastry, M. &amp; Hamilton, E. (2023)  Targeting HER2-positive breast cancer: advances and future directions.  <i>Nat. Rev. Drug Discov.<\/i>, 22, 101-126.","DOI":"10.1038\/s41573-022-00579-0"},{"key":"42","unstructured":"Tang, D.Y. &amp; Huang, J.Y. (2022)  Effect of Pyrotinib Combined with TAC Chemotherapy on Disease Control and Expression of IGF-1 and EGFR Protein in Locally Advanced HER2 Positive Breast Cancer.  <i>Medical Innovation of China<\/i>, 19, 078-082."},{"key":"43","doi-asserted-by":"crossref","unstructured":"Tian, C., Wang, M., Liu, H., Liu, J., Xu, M. &amp; Ma, L. (2023)  Efficacy and safety of neoadjuvant pyrotinib plus docetaxel\/liposomal doxorubicin\/cyclophosphamide for HER2-positive breast cancer.  <i>Ir. J. Med. Sci.<\/i>, 192, 1041-1049.","DOI":"10.1007\/s11845-022-03093-9"},{"key":"44","doi-asserted-by":"crossref","unstructured":"Van Sebille, Y.Z., Gibson, R.J., Wardill, H.R. &amp; Bowen, J.M. (2015)  ErbB small molecule tyrosine kinase inhibitor (TKI)  induced diarrhoea: Chloride secretion as a mechanistic hypothesis.  <i>Cancer Treat. Rev.<\/i>, 41, 646-652.","DOI":"10.1016\/j.ctrv.2015.05.011"},{"key":"45","doi-asserted-by":"crossref","unstructured":"Wang, C., Deng, S., Chen, J., Xu, X., Hu, X., Kong, D., Liang, G., Yuan, X., Li, Y. &amp; Wang, X. (2021)  The Synergistic Effects of Pyrotinib Combined With Adriamycin on HER2-Positive Breast Cancer.  <i>Front. Oncol.<\/i>, 11, 616443.","DOI":"10.3389\/fonc.2021.616443"},{"key":"46","doi-asserted-by":"crossref","unstructured":"Wang, H., Cao, H. &amp; Guo, Z. (2023)  Efficacy, toxicity and prognostic factors of pyrotinib-involved neoadjuvant therapy in HER2-positive breast cancer: A retrospective study.  <i>Oncol. Lett.<\/i>, 26, 314.","DOI":"10.3892\/ol.2023.13900"},{"key":"47","unstructured":"Wells, G.A., Shea, B., Connell, O.D., Peterson, J., Welch, V., Losos, M. &amp; Tugwell, P. (2000)  The Newcastle-Ottawa Scale (NOS)  for assessing the quality of nonrandomized studies in meta-analyses  http:\/\/www.ohri.ca\/programs\/clinical_epidemiology\/oxford.asp  [<i>Accessed:<\/i> April 2, 2024]."},{"key":"48","doi-asserted-by":"crossref","unstructured":"Wu, J., Jiang, Z., Liu, Z., Yang, B., Yang, H., Tang, J., Wang, K., Liu, Y., Wang, H., Fu, P., Zhang, S., Liu, Q., Wang, S., Huang, J., Wang, C., et al.  (2022)  Neoadjuvant pyrotinib, trastuzumab, and docetaxel for HER2-positive breast cancer (PHEDRA): a double-blind, randomized phase 3 trial.  <i>BMC Med.<\/i>, 20, 498.","DOI":"10.1186\/s12916-022-02708-3"},{"key":"49","doi-asserted-by":"crossref","unstructured":"Xu, B., Yan, M., Ma, F., Hu, X., Feng, J., Ouyang, Q., Tong, Z., Li, H., Zhang, Q., Sun, T., Wang, X., Yin, Y., Cheng, Y., Li, W., Gu, Y., et al.  (2021)  Pyrotinib plus capecitabine versus lapatinib plus capecitabine for the treatment of HER2-positive metastatic breast cancer (PHOEBE): a multicentre, open-label, randomised, controlled, phase 3 trial.  <i>Lancet Oncol.<\/i>, 22, 351-360.","DOI":"10.1016\/S1470-2045(20)30702-6"},{"key":"50","unstructured":"Xuhong, J.C., Qi, X.W., Zhang, Y. &amp; Jiang, J. (2019)  Mechanism, safety and efficacy of three tyrosine kinase inhibitors lapatinib, neratinib and pyrotinib in HER2-positive breast cancer.  <i>Am. J. Cancer Res.<\/i>, 9, 2103-2119."},{"key":"51","doi-asserted-by":"crossref","unstructured":"Yin, W., Wang, Y., Wu, Z., Ye, Y., Zhou, L., Xu, S., Lin, Y., Du, Y., Yan, T., Yang, F., Zhang, J., Liu, Q. &amp; Lu, J. (2022)  Neoadjuvant Trastuzumab and Pyrotinib for Locally Advanced HER2-Positive Breast Cancer (NeoATP): Primary Analysis of a Phase II Study.  <i>Clin. Cancer Res.<\/i>, 28, 3677-3685.","DOI":"10.1158\/1078-0432.CCR-22-0446"},{"key":"52","doi-asserted-by":"crossref","unstructured":"Yu, Z.G., Xiong, B., Yang, Z., Kong, L., Wang, F. &amp; Wang, Y. (2021)  The addition of pyrotinib in early or locally advanced HER2-positive breast cancer patients with no response to two cycles of neoadjuvant therapy: A prospective, multicenter study.  <i>Ann. Oncol.<\/i>, 32, S428.","DOI":"10.1016\/j.annonc.2021.08.436"},{"key":"53","doi-asserted-by":"crossref","unstructured":"Yuan, Y., Liu, X., Cai, Y. &amp; Li, W. (2023)  Pyrotinib versus lapatinib therapy for HER2 positive metastatic breast cancer patients after first-line treatment failure: A meta-analysis and systematic review.  <i>PLoS One<\/i>, 18, e0279775.","DOI":"10.1371\/journal.pone.0279775"},{"key":"54","doi-asserted-by":"crossref","unstructured":"Zhang, X., Zhang, S., Li, Z., Niu, F., Cai, H., Li, X., Han, M., Huang, R. &amp; Liu, Y. (2022)  Pyrotinib combined with EC-TH neoadjuvant therapy for patients with HER2-positive breast cancer: A multicenter, randomized, phase II, open-label trial, 40, e12604-e12604.","DOI":"10.1200\/JCO.2022.40.16_suppl.e12604"},{"key":"55","unstructured":"Zheng, X.X., Zhang, X.X., Wu, J., Gu, S.C., Jiang, X.L., Shi, X.H., Yuan, M., Lu, B.L., Qiu, X., Bai, J.Y., Yang, P. &amp; Guan, X.Q. (2021)  Efficacy and safety of pyrotinib combined with TCbH regimen in treatment of young patients with locally advanced HER-2 positive breast cancer at first diagnosis.  <i>Chinese Journal of General Surgery<\/i>, 30, 1304-1310."},{"key":"56","doi-asserted-by":"crossref","unstructured":"Zhu, J., Jiao, D., Wang, C., Lu, Z., Chen, X., Li, L., Sun, X., Qin, L., Guo, X., Zhang, C., Qiao, J., Yan, M., Cui, S. &amp; Liu, Z. (2022)  Neoadjuvant Efficacy of Three Targeted Therapy Strategies for HER2-Positive Breast Cancer Based on the Same Chemotherapy Regimen.  <i>Cancers <\/i>(<i>Basel<\/i>), 14, 4508.","DOI":"10.3390\/cancers14184508"}],"container-title":["The Tohoku Journal of Experimental Medicine"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.jstage.jst.go.jp\/article\/tjem\/263\/3\/263_2024.J026\/_pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,9,7]],"date-time":"2024-09-07T03:43:41Z","timestamp":1725680621000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.jstage.jst.go.jp\/article\/tjem\/263\/3\/263_2024.J026\/_article"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024]]},"references-count":56,"journal-issue":{"issue":"3","published-print":{"date-parts":[[2024]]}},"URL":"https:\/\/doi.org\/10.1620\/tjem.2024.j026","relation":{},"ISSN":["0040-8727","1349-3329"],"issn-type":[{"type":"print","value":"0040-8727"},{"type":"electronic","value":"1349-3329"}],"subject":[],"published":{"date-parts":[[2024]]},"article-number":"2024.J026"}}